Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo.

OBJECTIVE To compare the efficacy and safety of using a combination of fluticasone propionate (FP) and UV-A with that of either drug used alone in the long-term treatment of vitiligo. DESIGN Prospective, randomized, controlled, left-right comparison study. Repigmentation was judged by a single dermatologist (L.N.-K.) and skin thickness was scored by a pathologist (using biopsy samples), a dermatologist (L.N.-K.) (visually), and patients (using a standard questionnaire). SETTING Netherlands Institute for Pigmentary Disorders, Amsterdam. PATIENTS Patients with lesions on arms, legs, and trunk were treated on 2 symmetrical lesions for 9 months with FP alone and a combination of FP and UV-A (FP group) or with UV-A alone and a combination of FP and UV-A (UV-A group). Fluticasone propionate cream was applied once daily at about bedtime, and UV-A (10 J/cm2) exposure was twice a week. Patients attended the clinic at 3-month intervals. RESULTS One hundred thirty-five patients were included, 96 of whom were evaluable after 9 months. Patients not reaching the end point withdrew because of insufficient repigmentation (n = 23), decreased motivation (n = 11), or protocol violations (n = 5). No patient (irrespective of whether they withdrew) experienced any adverse effects. The FP and UV-A groups were comparable with respect to sex, age, and location of lesions. On average, combination treatment was 3 times more effective than either UV-A or FP treatment alone. In the FP group, no atrophy was seen after 9 months with either treatment. In the UV-A group, a little atrophy was detected twice: as well during UV-A treatment alone as during combination treatment. CONCLUSIONS Combination treatment with FP and UV-A is much more effective in reaching complete repigmentation than are FP and UV-A used alone, but large inter-individual differences occur. Fluticasone propionate, UV-A, and a combination of FP and UV-A seem to be safe for long-term treatment of vitiligo.

[1]  Mishima Yutaka M. D.,et al.  Dendritic cell dynamics in progressive depigmentations , 1972, Archiv für dermatologische Forschung.

[2]  L. Wiseman,et al.  Topical fluticasone propionate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. , 1997, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[3]  M. Lebwohl.  Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. , 1996, Cutis.

[4]  L. Juhlin.  Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-17-butyrate cream, 0.1%, in the treatment of eczema. , 1996, Cutis.

[5]  C. Tanaka,et al.  Glucocorticoid stimulates melanogenesis and tyrosinase gene expression in B16 melanoma cells. , 1991, Pigment cell research.

[6]  S. Yawalkar,et al.  Treatment of Localized Vitiligo with Ulobetasol Cream , 1990, International journal of dermatology.

[7]  J. Kumari.  Vitiligo treated with topical clobetasol propionate. , 1984, Archives of dermatology.

[8]  G. Naughton,et al.  Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. , 1983, The Journal of investigative dermatology.

[9]  N. Lowe,et al.  Association of HLA-DR4 with vitiligo. , 1983, Journal of the American Academy of Dermatology.

[10]  R. Clayton.  A double‐blind trial of 0.05% clobetasol proprionate in the treatment of vitiligo , 1977, The British journal of dermatology.

[11]  S. Bleehen.  The treatment of vitiligo with topical corticosteroids , 1976 .

[12]  J. Carruthers,et al.  Observations on the systemic effect of topical clobetasol propionate (Dermovate). , 1975, British medical journal.

[13]  E. Kandil.  Treatment of vitiligo with O·1% betamethasone 17‐valerate in isopropyl alcohol—a double‐blind trial , 1974 .

[14]  E. Kandil.  Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. , 1974, The British journal of dermatology.

[15]  H. Neering,et al.  Treatment of vitiligo by local application of betamethasone 17-valerate in a dimethyl sulfoxide cream base. , 1973, Dermatologica.

[16]  D. Stevanović.  CORTICOSTEROID‐INDUCED ATROPHY OF THE SKIN WITH TELANGIECTASIA , 1972, The British journal of dermatology.

[17]  H. Pinkus,et al.  Dendritic cell dynamics in progressive depigmentations. Distinctive cytokinetics of -dendritic cells revealed by electron microscopy. , 1972, Archiv fur dermatologische Forschung.

[18]  E. Kandil.  Vitiligo – Response to 0.2 % Betamethasone 17-Valerate in Flexible Collodion , 1970 .

[19]  I. Sneddon.  Disorders of pigmentation. , 1970, The Practitioner.

[20]  J. Brostoff.  Autoantibodies in patients with vitiligo. , 1969, Lancet.